ECSP19043120A - Pirrolopirimidinas como potenciadores de cftr - Google Patents

Pirrolopirimidinas como potenciadores de cftr

Info

Publication number
ECSP19043120A
ECSP19043120A ECSENADI201943120A ECDI201943120A ECSP19043120A EC SP19043120 A ECSP19043120 A EC SP19043120A EC SENADI201943120 A ECSENADI201943120 A EC SENADI201943120A EC DI201943120 A ECDI201943120 A EC DI201943120A EC SP19043120 A ECSP19043120 A EC SP19043120A
Authority
EC
Ecuador
Prior art keywords
cftr
compounds
cystic fibrosis
pyrrolopyrimidines
potentials
Prior art date
Application number
ECSENADI201943120A
Other languages
English (en)
Spanish (es)
Inventor
Ivan Efremov
Rajiah Denny
John Mathias
Josep Strohbach
Lori Gavrin
David Limburg
Atli Thorarensen
Christoph Zapf
Daniel Elbaum
Original Assignee
Cystic Fibrosis Found Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cystic Fibrosis Found Therapeutics Inc filed Critical Cystic Fibrosis Found Therapeutics Inc
Publication of ECSP19043120A publication Critical patent/ECSP19043120A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
ECSENADI201943120A 2016-11-18 2019-06-17 Pirrolopirimidinas como potenciadores de cftr ECSP19043120A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662423919P 2016-11-18 2016-11-18

Publications (1)

Publication Number Publication Date
ECSP19043120A true ECSP19043120A (es) 2019-08-30

Family

ID=62144793

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201943120A ECSP19043120A (es) 2016-11-18 2019-06-17 Pirrolopirimidinas como potenciadores de cftr

Country Status (21)

Country Link
US (5) US10301315B2 (https=)
EP (2) EP3541390B1 (https=)
JP (3) JP6978507B2 (https=)
KR (2) KR102585398B1 (https=)
CN (2) CN110337294B (https=)
AU (2) AU2017362350B2 (https=)
CL (1) CL2019001334A1 (https=)
CO (1) CO2019005993A2 (https=)
CR (1) CR20190292A (https=)
DO (1) DOP2019000126A (https=)
EC (1) ECSP19043120A (https=)
ES (1) ES2983686T3 (https=)
IL (3) IL314404B2 (https=)
MX (2) MX2021012639A (https=)
PE (1) PE20200739A1 (https=)
PH (1) PH12019501098A1 (https=)
PL (1) PL3541390T3 (https=)
RU (2) RU2757457C2 (https=)
SG (1) SG10202106949XA (https=)
UA (1) UA125400C2 (https=)
WO (1) WO2018094137A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9487495B2 (en) 2012-01-06 2016-11-08 The Scripts Research Institute Carbamate compounds and of making and using same
TWI735416B (zh) 2014-10-06 2021-08-11 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
MA44126A (fr) * 2015-12-22 2018-10-31 Proteostasis Therapeutics Inc Méthodes de traitement de maladies et troubles pulmonaires
SI3519401T1 (sl) 2016-09-30 2022-01-31 Vertex Pharmaceuticals Incorporated Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja
AU2017362350B2 (en) 2016-11-18 2021-12-23 Cystic Fibrosis Foundation Pyrrolopyrimidines as CFTR potentiators
CN110267948B (zh) 2016-12-09 2023-12-08 弗特克斯药品有限公司 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
US10131670B2 (en) 2016-12-16 2018-11-20 Cystic Fibrosis Foundation Therapeutics, Inc. Bicyclic heteroaryl derivatives as CFTR potentiators
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
KR102716244B1 (ko) 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
AU2019222758B2 (en) 2018-02-15 2022-07-07 Vertex Pharmaceuticals Incorporated Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
AU2020290094B2 (en) * 2019-06-10 2024-01-18 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
BR112022000507A2 (pt) 2019-07-15 2022-05-10 Novartis Ag Formulações de (s)-3-amino-6-metóxi-n-(3,3,3-trifluoro-2-hidróxi-2-metilpropil)-5-(trifluorometil)picolinamida
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
CA3150162A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
CN111138439B (zh) * 2020-01-17 2021-06-25 厦门大学 氟代吡咯并嘧啶类化合物及其制备方法和应用
WO2021176049A1 (en) 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Pyrazolopyrazines acting on cancers via inhibition of cdk12
IL300413A (en) 2020-08-13 2023-04-01 Vertex Pharma Crystal forms of CFTR modulators
KR20230052954A (ko) 2020-08-20 2023-04-20 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 점액 과다분비를 특징으로 하는 호흡기 질환의 치료 방법
EP4225762A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2021397294A1 (en) 2020-12-10 2023-07-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TW202425990A (zh) * 2022-11-02 2024-07-01 南韓商日東製藥股份有限公司 包含ｃｆｔｒ調節劑化合物之點眼用組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990067704A (ko) * 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
US5869485A (en) 1994-09-29 1999-02-09 Novartis Finance Corp. Pyrrolo 2,3-d!pyrimidines and their use
ID29028A (id) 1998-09-18 2001-07-26 Basf Ag Pirolopirimidina sebagai penghambat protein kinase
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
WO2002096867A2 (en) 2001-05-30 2002-12-05 Lg Biomedical Institute Inhibitors of protein kinase for the treatment of disease
DE10135815A1 (de) 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
WO2004100868A2 (en) * 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
JP2007520559A (ja) * 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
EP1913000B1 (en) 2005-07-29 2012-01-11 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
WO2007064931A2 (en) 2005-12-02 2007-06-07 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
ES2545907T3 (es) * 2005-12-29 2015-09-16 Abbvie Inc. Inhibidores de proteína quinasa
EA200801968A1 (ru) * 2006-03-11 2009-02-27 Вернэлис (Р&Д) Лтд. Пирролопиримидиновые производные, используемые в качестве ингибиторов hsp90
WO2007114926A2 (en) * 2006-04-04 2007-10-11 The Regents Of The University Of California Kinase antagonists
CA2705303A1 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
EA024252B1 (ru) 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
US20130035325A1 (en) 2009-11-16 2013-02-07 The Regents Of The University Of California Kinase inhibitors
CN102770133A (zh) 2010-02-05 2012-11-07 拜耳知识产权有限责任公司 用于治疗囊性纤维化的单独和与PDE5抑制剂组合的sGC刺激剂或sGC激活剂
WO2013071232A1 (en) 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions and methods for inhibition of tbl-1 binding to disease-associated molecules
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014060431A1 (en) * 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
CN105431437B (zh) 2013-07-02 2020-03-10 理森制药股份公司 PI3K蛋白激酶抑制剂，特别是δ抑制剂和/或γ抑制剂
WO2015091532A1 (en) * 2013-12-19 2015-06-25 Almirall, S.A. Pyrrolopyrimidine derivatives as pi3k inhibitors
TWI735416B (zh) 2014-10-06 2021-08-11 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
AU2017362350B2 (en) 2016-11-18 2021-12-23 Cystic Fibrosis Foundation Pyrrolopyrimidines as CFTR potentiators
US10131670B2 (en) 2016-12-16 2018-11-20 Cystic Fibrosis Foundation Therapeutics, Inc. Bicyclic heteroaryl derivatives as CFTR potentiators

Also Published As

Publication number Publication date
PE20200739A1 (es) 2020-07-24
SG10202106949XA (en) 2021-07-29
JP6978507B2 (ja) 2021-12-08
JP2023182694A (ja) 2023-12-26
IL266668B (en) 2022-10-01
RU2757457C2 (ru) 2021-10-18
CL2019001334A1 (es) 2019-11-15
JP7592814B2 (ja) 2024-12-02
EP3541390C0 (en) 2024-05-01
IL296279A (en) 2022-11-01
CN110337294A (zh) 2019-10-15
EP3541390B1 (en) 2024-05-01
NZ754085A (en) 2025-05-02
KR20190110088A (ko) 2019-09-27
JP2022024023A (ja) 2022-02-08
EP3541390A1 (en) 2019-09-25
ES2983686T3 (es) 2024-10-24
PH12019501098A1 (en) 2019-09-09
MX387203B (es) 2025-03-18
US20180141954A1 (en) 2018-05-24
RU2021129721A (ru) 2021-11-26
AU2022201816A1 (en) 2022-04-07
AU2017362350A1 (en) 2019-06-20
JP2020510668A (ja) 2020-04-09
JP7360434B2 (ja) 2023-10-12
US20190225621A1 (en) 2019-07-25
KR102585398B1 (ko) 2023-10-10
BR112019010167A2 (pt) 2019-09-17
MX2019005822A (es) 2019-09-09
AU2017362350B2 (en) 2021-12-23
IL314404A (en) 2024-09-01
CN115850268B (zh) 2025-06-27
IL266668A (en) 2019-07-31
US12612409B2 (en) 2026-04-28
IL314404B1 (en) 2025-09-01
EP4424311A3 (en) 2024-12-18
IL266668B2 (en) 2023-02-01
EP4424311A2 (en) 2024-09-04
RU2019118623A (ru) 2020-12-21
WO2018094137A1 (en) 2018-05-24
PL3541390T3 (pl) 2024-09-09
AU2022201816B2 (en) 2024-02-15
IL314404B2 (en) 2026-01-01
EP3541390A4 (en) 2020-06-24
KR102824092B1 (ko) 2025-06-25
UA125400C2 (uk) 2022-03-02
AU2022201816A8 (en) 2022-04-21
US10301315B2 (en) 2019-05-28
KR20230146104A (ko) 2023-10-18
DOP2019000126A (es) 2019-08-30
MX2021012639A (es) 2022-10-03
CN115850268A (zh) 2023-03-28
CN110337294B (zh) 2022-11-01
US20200017512A1 (en) 2020-01-16
CA3044050A1 (en) 2018-05-24
US10494374B2 (en) 2019-12-03
US20210171534A1 (en) 2021-06-10
CO2019005993A2 (es) 2019-07-31
CR20190292A (es) 2019-09-03
US20230250100A1 (en) 2023-08-10
RU2019118623A3 (https=) 2021-03-18

Similar Documents

Publication Publication Date Title
ECSP19043120A (es) Pirrolopirimidinas como potenciadores de cftr
MX2019007135A (es) Derivados de heteroarilo biciclico como potenciadores de cftr.
CU20120139A7 (es) Derivado de piridina y pirazina para el tratamiento de fibrosis quística(cf)
DOP2018000020A (es) Tricíclicos sustituidos y método para usarlos
BR112018007161A2 (pt) pirazolo[3,4-b]piridin-6-carboxamidas n-sulfoniladas e métodos de uso
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
CR9832A (es) Compuestos de pirimidina amida como inhibidores de pgds
CO2019008986A2 (es) Derivados de tirosinamida como inhibidores de rho-quinasa
BR112018007145A2 (pt) ácidos pirazolo[3,4-b]piridin-6-carboxílicos substituídos e o seu uso
UY40365A (es) Cromanos sustituidos y sales farmacéuticamente aceptables de los mismos, y composiciones que los comprenden
ECSP16054826A (es) Derivados Novedosos de Amino Pirimidina
MX2018013002A (es) Moduladores de la proteina reguladora de la conductancia transmembrana de la fibrosis quistica.
CO6321265A2 (es) Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso
PA8774101A1 (es) Compuesto de pirmidina
DOP2016000175A (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
CL2014000122A1 (es) Compuestos derivados de indazol, inhibidores de janus quinasa (jak); composicion farmaceutica que los comprende; y su uso para tratar rinitis alergica, congestion nasal, asma, bronquitis cronica, artritis, insuficiencia cardiaca, colitis ulcerativa, infeccion viral y bacteriana, cancer y alzheimer, entre otras enfermedades.
ECSP088741A (es) Derivados de benzotriazol como agonistas del adrenoreceptor beta2
BR112014016648A2 (pt) derivados policíclicos, processo de preparação e uso farmacêutico dos mesmos
SV2009002861A (es) Compuestos de pirimidina amida como inhibidores de pgds
EA202092976A1 (ru) Устойчивые фармацевтические композиции для дозированных ингаляторов под давлением
ECSP10010606A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3
WO2015009731A3 (en) Azacyclic constrained analogs of fty720
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
UY30934A1 (es) Producto farmacéutico combinacion de un antagonista del receptor de quimioquina 1 (ccr1) y un antagonista muscarinico, composiciones farmacéuticas y aplicaciones.
PT115583A (pt) Processo contínuo para a preparação de medicamentos anticolinérgicos